{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:17:50Z","timestamp":1780316270141,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T00:00:00Z","timestamp":1520812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T00:00:00Z","timestamp":1520812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015453","name":"Adamas Pharmaceuticals, Inc.","doi-asserted-by":"crossref","award":["NCT02136914"],"award-info":[{"award-number":["NCT02136914"]}],"id":[{"id":"10.13039\/100015453","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Adamas Pharmaceuticals, Inc","award":["NCT02274766"],"award-info":[{"award-number":["NCT02274766"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40263-018-0498-4","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T10:55:10Z","timestamp":1520852110000},"page":"387-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"32","author":[{"given":"Lawrence W.","family":"Elmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge L.","family":"Juncos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan R.","family":"Criswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Parashos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Felt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Patni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,12]]},"reference":[{"issue":"7","key":"498_CR1","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s00018-015-2101-1","volume":"73","author":"D Lindholm","year":"2016","unstructured":"Lindholm D, Makela J, Di Liberto V, Mudo G, Belluardo N, Eriksson O, et al. Current disease modifying approaches to treat Parkinson\u2019s disease. Cell Mol Life Sci. 2016;73(7):1365\u201379.","journal-title":"Cell Mol Life Sci"},{"issue":"Suppl 2","key":"498_CR2","doi-asserted-by":"publisher","first-page":"S249","DOI":"10.1007\/s00415-010-5741-y","volume":"257","author":"O Hornykiewicz","year":"2010","unstructured":"Hornykiewicz O. A brief history of levodopa. J Neurol. 2010;257(Suppl 2):S249\u201352.","journal-title":"J Neurol"},{"issue":"14 Suppl 1","key":"498_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1212\/WNL.0000000000002509","volume":"86","author":"PA LeWitt","year":"2016","unstructured":"LeWitt PA, Fahn S. Levodopa therapy for Parkinson disease: a look backward and forward. Neurology. 2016;86(14 Suppl 1):S3\u201312.","journal-title":"Neurology."},{"issue":"16","key":"498_CR4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670\u201383.","journal-title":"JAMA"},{"issue":"3","key":"498_CR5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448\u201358.","journal-title":"Mov Disord"},{"issue":"21 Suppl 4","key":"498_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","volume":"72","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72(21 Suppl 4):S1\u2013136.","journal-title":"Neurology."},{"issue":"Suppl 11","key":"498_CR7","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1002\/mds.20458","volume":"20","author":"J Jankovic","year":"2005","unstructured":"Jankovic J. Motor fluctuations and dyskinesias in Parkinson\u2019s disease: clinical manifestations. Mov Disord. 2005;20(Suppl 11):S11\u20136.","journal-title":"Mov Disord"},{"issue":"Suppl","key":"498_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/jnnp.52.Suppl.29","volume":"52","author":"AJ Lees","year":"1989","unstructured":"Lees AJ. The on-off phenomenon. J Neurol Neurosurg Psychiatry. 1989;52(Suppl):29\u201337.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"498_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","volume":"20","author":"S Chapuis","year":"2005","unstructured":"Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson\u2019s disease on the quality of life. Mov Disord. 2005;20(2):224\u201330.","journal-title":"Mov Disord"},{"issue":"9","key":"498_CR10","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.parkreldis.2014.06.001","volume":"20","author":"MC Hechtner","year":"2014","unstructured":"Hechtner MC, Vogt T, Zollner Y, Schroder S, Sauer JB, Binder H, et al. Quality of life in Parkinson\u2019s disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat Disord. 2014;20(9):969\u201374.","journal-title":"Parkinsonism Relat Disord."},{"issue":"10","key":"498_CR11","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00702-015-1396-2","volume":"122","author":"O Rascol","year":"2015","unstructured":"Rascol O, Perez-Lloret S, Damier P, Delval A, Derkinderen P, Destee A, et al. Falls in ambulatory non-demented patients with Parkinson\u2019s disease. J Neural Transm (Vienna). 2015;122(10):1447\u201355.","journal-title":"J Neural Transm (Vienna)."},{"issue":"1\u20132","key":"498_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jns.2012.05.029","volume":"319","author":"DC Suh","year":"2012","unstructured":"Suh DC, Pahwa R, Mallya U. Treatment patterns and associated costs with Parkinson\u2019s disease levodopa induced dyskinesia. J Neurol Sci. 2012;319(1\u20132):24\u201331.","journal-title":"J Neurol Sci"},{"issue":"8","key":"498_CR13","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00702-007-0718-4","volume":"114","author":"T Muller","year":"2007","unstructured":"Muller T, Woitalla D, Russ H, Hock K, Haeger DA. Prevalence and treatment strategies of dyskinesia in patients with Parkinson\u2019s disease. J Neural Transm (Vienna). 2007;114(8):1023\u20136.","journal-title":"J Neural Transm (Vienna)."},{"issue":"12","key":"498_CR14","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s40263-014-0205-z","volume":"28","author":"E Schaeffer","year":"2014","unstructured":"Schaeffer E, Pilotto A, Berg D. Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson\u2019s disease. CNS Drugs. 2014;28(12):1155\u201384.","journal-title":"CNS Drugs"},{"key":"498_CR15","unstructured":"Chase TN, Oh JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol. 2000;47(4 Suppl 1):S122\u20139 (discussion S129\u2013S130)."},{"issue":"4","key":"498_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0149-7634(96)00037-1","volume":"21","author":"W Danysz","year":"1997","unstructured":"Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents: preclinical studies. Neurosci Biobehav Rev. 1997;21(4):455\u201368.","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"498_CR17","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1212\/WNL.0000000000000050","volume":"82","author":"F Ory-Magne","year":"2014","unstructured":"Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology. 2014;82(4):300\u20137.","journal-title":"Neurology."},{"issue":"5","key":"498_CR18","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","volume":"50","author":"L Verhagen Metman","year":"1998","unstructured":"Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson\u2019s disease. Neurology. 1998;50(5):1323\u20136.","journal-title":"Neurology."},{"issue":"11","key":"498_CR19","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/archneur.56.11.1383","volume":"56","author":"LV Metman","year":"1999","unstructured":"Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol. 1999;56(11):1383\u20136.","journal-title":"Arch Neurol"},{"issue":"10","key":"498_CR20","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/mds.23034","volume":"25","author":"E Wolf","year":"2010","unstructured":"Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson\u2019s disease. Mov Disord. 2010;25(10):1357\u201363.","journal-title":"Mov Disord"},{"key":"498_CR21","doi-asserted-by":"crossref","unstructured":"Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson\u2019s disease. Cochrane Database Syst Rev. 2003;(2):CD003467.","DOI":"10.1002\/14651858.CD003467"},{"issue":"1","key":"498_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/jnnp.2004.036558","volume":"75","author":"A Thomas","year":"2004","unstructured":"Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2004;75(1):141\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"498_CR23","unstructured":"GOCOVRI (amantadine) extended release capsules for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208944lbl.pdf."},{"issue":"6","key":"498_CR24","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/mds.26159","volume":"30","author":"R Pahwa","year":"2015","unstructured":"Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASED Study). Mov Disord. 2015;30(6):788\u201395.","journal-title":"Mov Disord"},{"issue":"8","key":"498_CR25","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/jamaneurol.2017.0943","volume":"74","author":"R Pahwa","year":"2017","unstructured":"Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, et al. ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial. JAMA Neurol. 2017;74(8):941\u20139.","journal-title":"JAMA Neurol."},{"issue":"12","key":"498_CR26","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/mds.27131","volume":"32","author":"W Oertel","year":"2017","unstructured":"Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 3). Mov Disord. 2017;32(12):1701\u20139.","journal-title":"Mov Disord"},{"issue":"3","key":"498_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"498_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","volume":"23","author":"RA Hauser","year":"2000","unstructured":"Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O\u2019Brien CF, et al. A home diary to assess functional status in patients with Parkinson\u2019s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000;23(2):75\u201381.","journal-title":"Clin Neuropharmacol"},{"issue":"15","key":"498_CR29","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129\u201370.","journal-title":"Mov Disord"},{"issue":"16","key":"498_CR30","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1002\/mds.22341","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord. 2008;23(16):2398\u2013403.","journal-title":"Mov Disord"},{"key":"498_CR31","first-page":"216","volume-title":"ECDEU assessment manual for psychopharmacology","author":"National Institute of Mental Health, Early clinical drug, evaluation unit (ECDEU)","year":"1976","unstructured":"National Institute of Mental Health, Early clinical drug, evaluation unit (ECDEU). Clinical Global impressions. In: Guy W, editor. ECDEU assessment manual for psychopharmacology. National Institute of Mental Health: Rockville; 1976. p. 216\u201322."},{"issue":"3","key":"498_CR32","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.nbd.2003.07.003","volume":"14","author":"F Calon","year":"2003","unstructured":"Calon F, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson\u2019s disease. Neurobiol Dis. 2003;14(3):404\u201316.","journal-title":"Neurobiol Dis"},{"issue":"6","key":"498_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nrneurol.2009.62","volume":"5","author":"NJ Diederich","year":"2009","unstructured":"Diederich NJ, Fenelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009;5(6):331\u201342.","journal-title":"Nat Rev Neurol."}],"updated-by":[{"DOI":"10.1007\/s40263-018-0510-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T00:00:00Z","timestamp":1523318400000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-018-0498-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0498-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0498-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T01:37:23Z","timestamp":1612834643000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-018-0498-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,12]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["498"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0498-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40263-018-0510-z","asserted-by":"object"}]},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,12]]},"assertion":[{"value":"12 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Adamas Pharmaceuticals, Inc. funded these studies and analyses. Editorial assistance to the authors was provided by The Curry Rockefeller Group, LLC, and this assistance was funded by Adamas. Open access was funded by Adamas.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lawrence W. Elmer has received honoraria for speaking engagements from Lundbeck, Novartis, UCB Pharma, and Teva Neuroscience; has served as a paid consultant for Teva Neuroscience and UCB Pharma; has received honoraria as a member of advisory boards for Lundbeck, Teva Neuroscience, and UCB Pharma; and has received unrestricted educational grant support from Teva Neuroscience. Jorge L. Juncos reports research grants from the National Institute of Child Health and Human Development (NICHD), the Michael J. Fox Foundation, Adamas Pharmaceuticals, US WorldMeds, Psydon, and Neurocrine. Carlos Singer has received honoraria from Neurocrine, Revance, US WorldMeds, TEVA, and Acorda, and has received grants from Allergan, Adams, Pfizer, Synovia, the Parkinson\u2019s Foundation, National Institutes of Health (NIH), and the Huntington\u2019s Disease Society of America. Daniel D. Truong has received research grants from Ispen, Merz, Auspex, Daiichi Sankyo Pharma, AbbVie, National Institute of Neurological Disorders and Stroke, Kyowa, and Neurocrine. Susan R. Criswell has no relevant disclosures or conflicts of interest. Sotirios Parashos has no relevant disclosures or conflicts of interest. Unrelated to the subject matter of this study, Sotirios Parashos has received consultancies from Dong-A, research support from the Park Nicollet Foundation, National Parkinson Foundation, NINDS, Patient-Centered Outcomes Research Institute, Acorda Therapeutics, Astellas, Pharma2B, and Sunovion Pharmaceuticals. Larissa Felt, Reed Johnson, and Rajiv Patni are employees of and own stock in Adamas Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}